SCHEMBL3372967

SCHEMBL3372967

CCOC(=O)C(Cc1ccc(OCCc2csc(-c3ccccc3)n2)c(F)c1)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PPARG P37231 10/20 0.42
PPARA Q07869 8/20 0.42
ITGB3 P05106 1/20 0.42
ITGB1 P05556 1/20 0.42
ITGAV P06756 1/20 0.42
ITGA5 P08648 1/20 0.42
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ATM Q13315 1/20 0.41
LMNA P02545 1/20 0.41
PPARD Q03181 2/20 0.40
TP53 P04637 2/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374570 0.96 MAPT (0.41) PTPN2PTPN1PPARGPPARAITGB3
SCHEMBL3373587 0.93 LMNA (0.45) ITGB3ITGB1ITGAVITGA5MAPT
SCHEMBL3370731 0.93 PPARG (0.47) PTPN2PTPN1PPARGPPARAITGB3
SCHEMBL3374527 0.91 RAB9A (0.44) PPARGPPARAMAPTSMN1; SMN2ATM
SCHEMBL3372462 0.91 TP53 (0.47) MAPTTHRBSMN1; SMN2LMNATP53
SCHEMBL3374361 0.91 TP53 (0.38) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL3372856 0.90 TP53 (0.45) PPARGPPARAMAPTSMN1; SMN2LMNA
SCHEMBL3375172 0.90 TP53 (0.40) PPARGPPARAMAPTTHRBLMNA
SCHEMBL3372389 0.89 PPARG (0.45) PPARGPPARAMAPTTHRBSMN1; SMN2
SCHEMBL3369163 0.88 LMNA (0.45) PPARGPPARAITGB3ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR PTPN2 114/4885PTPN1 14/4885PPARG 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.